Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 23, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K

PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome.

Hui-Zi Chen1,2, Na Hyun Kim3, Daisuke Nishizaki4

  • 1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA. huchen@mcw.edu.

NPJ Genomic Medicine
|March 12, 2025
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes.

Therapeutic advances in medical oncology·2026
Same author

Navigating Complexity in the Precision Oncology Clinic: Pharmacists' Central Role in Drug Selection, Acquisition, and Dosing in a Real-World Clinic.

Journal of immunotherapy and precision oncology·2026
Same author

Universal Germline Genetic Testing in a Precision Oncology and Rare Cancer Clinic: Implementation and Outcomes.

JCO oncology advances·2026
Same author

A Novel DRD2 Antagonist, SD2-2305, Exerts Anticancer Effects in Colorectal Cancer Cells through G1 Arrest and Caspase-Dependent Apoptosis.

Biomolecules & therapeutics·2026
Same author

Job resignation between cancer diagnosis and surgery in patients with gastric and esophageal cancer: a multi-institutional cross-sectional study.

International journal of clinical oncology·2026
Same author

Emphysema severity-associated gut microbiota modulates smoke-induced emphysema: evidence from fecal microbiota transplantation.

Respiratory research·2026

High programmed cell death protein 1 (PD-1) RNA expression predicts better survival in cancer patients treated with immune checkpoint inhibitors (ICI). This finding highlights PD-1 as a key biomarker for ICI therapy outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Programmed cell death protein 1 (PD-1) is a crucial immune checkpoint receptor targeted by cancer immune checkpoint inhibitors (ICI).
  • Understanding PD-1 expression patterns and their clinical relevance is vital for optimizing cancer immunotherapy.

Purpose of the Study:

  • To investigate PD-1 transcript expression across diverse cancer types.
  • To correlate PD-1 expression with clinical outcomes, particularly in patients receiving ICI therapy.

Main Methods:

  • PD-1 RNA expression was analyzed as percentiles in 489 patients with advanced/metastatic disease across 31 cancer types.
  • Correlations between PD-1 expression and other immune checkpoint markers (CTLA-4, LAG-3, TIGIT) were assessed.
  • The association between high PD-1 expression and patient outcomes was evaluated in both immunotherapy-naïve and ICI-treated cohorts.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

212
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K

Related Experiment Videos

Last Updated: May 23, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

212
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K

Main Results:

  • PD-1 RNA expression exhibited significant variability across and within cancer types, with pancreatic and liver/bile duct cancers showing the highest prevalence of high PD-1 expression.
  • Elevated RNA expression of CTLA-4, LAG-3, and TIGIT were independently associated with high PD-1 expression.
  • While high PD-1 expression did not correlate with outcomes in immunotherapy-naïve patients, it was independently linked to prolonged survival in patients treated with ICIs (HR 0.40; 95% CI, 0.18-0.92).

Conclusions:

  • PD-1 transcript expression is a significant biomarker for predicting response and survival in patients undergoing cancer immune checkpoint inhibitor therapy.
  • Comprehensive immunogenomic profiling, including PD-1 expression, should be integrated into cancer management strategies to personalize treatment and improve patient outcomes.